Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can morning light boost melanoma treatment? new trial tests simple iPad therapy

NCT ID NCT07628894

Symptom relief Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether a home-based morning light therapy program can help people with advanced melanoma who are receiving tumor-infiltrating lymphocyte (TIL) therapy. The light therapy is delivered through an iPad app and aims to improve the body's natural sleep-wake cycle, which may be disrupted by cancer and hospital stays. The study will enroll 8 participants and focus on whether the light therapy is safe and easy to follow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Circadian-Optimized Light Therapy (COLT) via iPad app
What this could lead to
If it works, this could point toward a simple way to boost the effectiveness of TIL therapy for advanced melanoma by improving patients' sleep-wake cycles.
What could go wrong
This is a very early, small pilot study with only 8 participants. It is designed mainly to test if the light therapy is safe and doable, not whether it actually helps. The results may not apply to other patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 8 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Age: ≥ 18 years * Ability to read and understand English for questionnaires * Progression on or after immune checkpoint inhibitor therapy * Deemed eligible and consented for standard-of-care TIL therapy (lifileucel/Amtagvi) * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (typically required for TIL therapy; confirm with clinical standards of practice \[SOP\]) Exclusion Criteria: * Explicit Munich Chronotype Questionnaire (MCTQ) cutoffs (\< 2:00, \> 5:00) * Use of melatonin or pharmacologic sleep aids (e.g., zolpidem, trazodone, benzodiazepines) within 14 days prior to enrollment * Night shift work within the past 30 days or expected during the intervention * Travel across ≥ 2 time zones within the past 14 days * Diagnosed or suspected untreated moderate to severe obstructive sleep apnea * History of mania, hypomania, bipolar disorder, migraine (with or without photophobia), or active seizure disorder * Active psychosis, suicidal ideation, or recent psychiatric hospitalization (\< 3 months) * Ocular conditions exacerbated by bright light exposure * Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cutaneous melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cutaneous melanoma Clinical stage III cutaneous melanoma ajcc V8 Clinical stage IV cutaneous melanoma ajcc V8 Metastatic cutaneous melanoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.